Curis (CRIS) EBITDA Margin (2010 - 2025)
Curis' (CRIS) quarterly EBITDA Margin came in at 1723.99% in Q4 2025, up 199287.0% YoY from N/an in Q4 2024, and up 890.78% on a QoQ basis from 218.01% in Q3 2025.
Curis (CRIS) EBITDA Margin (2010 - 2025) Analysis & Trends
Curis (CRIS) has 16 years of EBITDA Margin data on file, last reported at 1723.99% in Q4 2025.
- Quarterly EBITDA Margin rose 199287.0% year-over-year to 1723.99% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 100.17% (up 27682.0% YoY) and the FY2025 annual result came in at 60.5%, up 34784.0% from the prior year.
- EBITDA Margin improved to 1723.99% in Q4 2025, from 218.01% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1723.99% in Q4 2025 to a low of 735.68% in Q1 2022.
- A 5-year average of 332.6% and a median of 431.67% in 2025 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 33367 bps — and 2025, when it soared 199287 bps.
- Tracing CRIS's EBITDA Margin over 5 years: stood at 400.86% in 2021, then grew by 12 bps to 354.0% in 2022, then fell by 28 bps to 452.49% in 2023, then jumped by 41 bps to 268.88% in 2024, then surged by 741 bps to 1723.99% in 2025.
- The last three EBITDA Margin figures came in at 1723.99% (Q4 2025), 218.01% (Q3 2025), and 300.15% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,723.99% |
| Sep 30, 2025 | -218.01% |
| Jun 30, 2025 | -300.15% |
| Mar 31, 2025 | -426.76% |
| Dec 31, 2024 | -268.88% |
| Sep 30, 2024 | -360.53% |
| Jun 30, 2024 | -491.44% |
| Mar 31, 2024 | -597.75% |
| Dec 31, 2023 | -452.49% |
| Sep 30, 2023 | -436.57% |
| Jun 30, 2023 | -552.48% |
| Mar 31, 2023 | -506.18% |
| Dec 31, 2022 | -354.00% |
| Sep 30, 2022 | -446.23% |
| Jun 30, 2022 | -629.38% |
| Mar 31, 2022 | -735.68% |
| Dec 31, 2021 | -400.86% |
| Sep 30, 2021 | -330.64% |
| Jun 30, 2021 | -465.88% |
| Mar 31, 2021 | -402.01% |